AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

Price Stock Quantity  
In DMSO USD 150 In stock
USD 120 In stock
USD 210 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

AG-1024  Chemical Structure

AG-1024 Chemical Structure
Molecular Weight: 305.17

Validation & Quality Control

Customer Reviews(2)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area

Product Description

Biological Activity

Description AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
Targets IGF-1R Insulin Receptor
IC50 7 μM [1] 57 μM [1]
In vitro AG-1024 blocks the IGF-1 receptor and IR autophosphorylation with IC50 of 7 μM and 57 μM, respectively. AG-1024 also inhibits the receptor tyrosine kinase activity towards exogenous substrates (TKA) with IC50 values of 18 μM and 80 μM, respectively. [1] AG-1024 (10 μM) inhibits cell proliferation in a time-dependent manner, and induces apoptosis in MCF-7 cells at 48 hours by 20.1% and >40% when combined with irradiation (10 Gy), more potently than that of irradiation (10 Gy) alone by 11.8%, which is associated with a down-regulation of phospho-Akt1 and bcl-2, and up-regulation of Bax, p53 and p21. [2] AG-1024 significantly inhibits melanoma cell proliferation with an IC50 of <50 nM in the absence of serum, by blocking MAPK/ERK2 signaling, subsequently rapidly inducing pRb dephosphorylation and activation, and eventually the formation of growth suppressive pRb-E2F complexes. [3] AG-1024 treatment down-regulates the expression of Bcr-Abl and P-Akt, and up-regulates DNA-PKcs expression in UT7-9 and Ba/F3-p210 cells, leading to decreased clonogenic survival and proliferation. AG-1024 also significantly inhibits the proliferation of cells resistant to the BCR-ABL inhibitor STI571, which correlates with a dose-dependent decrease in Bcr-Abl protein expression. [4]
In vivo Administration of AG-1024 at a dose of 30 μg for 10 days significantly inhibits the tumor growth of Ba/F3-p210 xenograft in mice. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibition of IGF-1- and insulin-stimulated cellular proliferation NIH-3T3 cells overexpressing IGF-1 or insulin receptors are plated on 96-well plates (2,000-5,000 cells/well) and maintained overnight in complete medium. Cells are then changed to DMEM containing 1% FBS in the presence of 10 nM IGF-1 or insulin and various concentrations of AG-1024 for 120 hours. Medium is replaced every 48 hours. At the indicated periods of time, the medium is aspirated from the wells and 100 μL MTT is added to each well. The cells are then incubated for 4 hours at 37 °C and lysed by addition of 100 μL isoamylic alcohol and shaking for 20 minutes. The plate is then read in the ELISA reader at 570 and 690 nm. The IC50 value is calculated at the 120-hour time point.

Cell Assay: [2]

Cell lines MCF-7
Concentrations Dissolved in DMSO, final concentration 10 μM
Incubation Time 24, 48 or 72 hours
Method Cells are exposed to AG-1024 for 24, 48 or 72 hours. For the determination of proliferation, cells are harvested and counted with trypan blue dye exclusion. Apoptosis is evaluated by dual staining of MCF-7 with fluoresceine anti-digoxigenin and propidium iodide. Briefly, fixed cells are washed with PBS, suspended in TdT buffer with TdT enzyme and Dig-dUTP for 60 minutes, and suspended in FITC blocking solution with anti-Dig-Fluorescein for 30 minutes at room temperature and kept in a dark place. Cells are then rinsed in buffer and resuspended in propidium iodide/RNase A solution for 30 minutes then analyzed by flow cytometry. For the assessment of phospho-Akt1, Bax, p53, bcl-2 and p21, cells are lysed and analyzed by western blot.

Animal Study: [4]

Animal Models Female nude mice implanted subcutaneously with Ba/F3-p210 cells
Formulation Dissolved in DMSO, and diluted in PBS
Dosages 30 μg/day
Administration Injected i.p
Solubility 1% DMSO/30% polyethylene glycol/1% Tween 80, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
1

References

Chemical Information

Download AG-1024 SDF
Molecular Weight (MW) 305.17
Formula

C14H13BrN2O

CAS No. 65678-07-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms
Solubility (25°C) * In vitro DMSO 61 mg/mL (199 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(3-bromo-5-tert-butyl-4-hydroxybenzylidene)malononitrile

Research Area

Customer Reviews (2)


Click to enlarge
Rating
Source Mol Endocrinol, 2011, 25(12), 2041-53. AG-1024 purchased from Selleck
Method Cell viability assay
Cell Lines A549 cells
Concentrations 0-10 μM
Incubation Time 48 h
Results Treating A549 cells with AZD6244 alone at concentrations rang-ing from 100 nM to 5 μMhad no effect on cell viabilities (Fig. A). However, when combined with 1 and 2 μM gossypol, AZD6244 noticeably reduced the number of viable cells in a dose-dependent manner. We also examined the inhibitory effects of an EGFR tyrosine kinase inhibitor AG1478 and an IGF-I receptor (IGF-IR) inhibitor AG1024 on breast cancer cell viability in combination with gossypol. Exposure to a low concentration of gossypol significantly sensitized SKBR3 and MCF-7 breast cancer cells to AG1478 and AG1024, respectively (Fig. B and C)

Click to enlarge
Rating
Source AG-1024 purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 5-15 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • CO-1686 (AVL-301)

    CO-1686 is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively. Phase 1/2.

  • AZD9291

    AZD9291 is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. Phase 3.

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R with IC50 of 86 nM, 27-fold greater selectivity for IGF-1R than InsR.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • OSI-906 (Linsitinib)

    OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 1/2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy AG-1024 | AG-1024 supplier | purchase AG-1024 | AG-1024 cost | AG-1024 manufacturer | order AG-1024 | AG-1024 distributor
Contact Us